Literature DB >> 23879

[Graft-versus-host reaction following granulocyte transfusion from a normal donor (author's transl)].

B Salfner, H Borberg, G Krüger, K Schumacher, E Siebel.   

Abstract

Graft-versus-Host disease following the transfusion of leukocytes from normal donor occured during remission-reinduction therapy in a 5 years old girl with acute lymphocytic leukemia. The clinical picture consisting of rash, diarrhea and somnolence was congruent with the diagnosis. Graft-versus-Host disease was confirmed by histology of skin biopsy and exclusion of other causes. The child survived the disease. We recommend the irradiation of leukocyte concentrates before transfusion.

Entities:  

Mesh：

Year:  1978        PMID： 23879     DOI： 10.1007/BF01002117

Source DB:  PubMed          Journal:  Blut        ISSN： 0006-5242


  10 in total

1.  [Therapy with granulocyte transfusions].

Authors:  M Schmitz-Valckenberg; H Borberg
Journal:  Dtsch Med Wochenschr       Date:  1976-10-01       Impact factor: 0.628

2.  Graft-versus-host disease. Morphologic variation and differential diagnosis in 8 cases of HL-A matched bone marrow transplantation.

Authors:  G R Krüger; C W Berard; R A DeLellis; R G Graw; R A Yankee; B G Leventhal; G N Rogentine; G P Herzig; R H Halterman; E S Henderson
Journal:  Am J Pathol       Date:  1971-05       Impact factor: 4.307

3.  Complication of bone-marrow transplantation. Graft-versus-host disease resulting from chronic-myelogenous-leukaemia leucocyte transfusions.

Authors:  R G Graw; C D Buckner; J Whang-Peng; B G Leventhal; G Krüger; C Berard; E S Henderson
Journal:  Lancet       Date:  1970-08-15       Impact factor: 79.321

4.  Graft versus host reaction in Wiskott-Aldrich syndrome: antemortem diagnosis of human GVH in an immunologic deficiency disease.

Authors:  S D Douglas; H H Fudenberg
Journal:  Vox Sang       Date:  1969-03       Impact factor: 2.144

5.  Erythroid homograft following leukocyte transfusion in a patient with acute leukemia. I. Clinical studies and implications.

Authors:  R H Levin; J Whang; P P Carbone; E J Freireich
Journal:  Blood       Date:  1965-11       Impact factor: 22.113

6.  Study of factors determining the usefulness and complications of leukocyte transfusions.

Authors:  L Schwarzenberg; G Mathé; J L Amiel; A Cattan; M Schneider; J R Schlumberger
Journal:  Am J Med       Date:  1967-08       Impact factor: 4.965

7.  Fatal graft-vs.-host reaction following transfusion of allogeneic blood and plasma in infants with combined immunodeficiency disease.

Authors:  B H Park; R A Good; J Gate; B Burke
Journal:  Transplant Proc       Date:  1974-12       Impact factor: 1.066

8.  White blood cell transfusions.

Authors:  L Schwarzenberg; G Mathé; J de Grouchy; C de Nava; M J de Vries; J L Amiel; A Cattan; M Schneider; J R Schlumberger
Journal:  Isr J Med Sci       Date:  1965-09

9.  Graft-vs-host reaction following a single blood transfusion.

Authors:  W E Hathaway; V A Fulginiti; C W Pierce; J H Githens; D S Pearlman; F Muschenheim; C H Kempe
Journal:  JAMA       Date:  1967-09-25       Impact factor: 56.272

10.  Fatal graft-versus-host disease following transfusion of granulocytes from normal donors.

Authors:  J M Ford; M H Cullen; J J Lucey; J S Tobias; T A Lister
Journal:  Lancet       Date:  1976-11-27       Impact factor: 79.321
  10 in total
  3 in total

1.  Graft-versus-host disease following blood transfusions.

Authors:  H Pflieger
Journal:  Blut       Date:  1983-02

2.  Fatal graft-versus-host reaction following granulocyte transfusions.

Authors:  W Schmidmeier; W Feil; W Gebhart; W Grisold; F Gschnait; W Hinterberger; P Höcker; K Jellinger; R Krepler; E Machacek
Journal:  Blut       Date:  1982-08

3.  Graft-versus-host reaction after blood transfusion in a patient with cellular immunodeficiency: the role of histocompatibility testing.

Authors:  D Niethammer; S F Goldmann; H D Flad; W Meigel; U Töllner; F Pohlandt; B Heymer; E Kleihauer
Journal:  Eur J Pediatr       Date:  1979-09       Impact factor: 3.183
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.